Sopharma AD-Sofia (WAR:SPH) Notes Receivable: zł0 Mil (As of Mar. 2026)


WAR:SPH Sopharma AD-Sofia WAR:SPH
66 GF Score
Price zł7.70
GF Value zł13.51
Valuation Possible Value Trap
! 3 Warning Signs
View Full Analysis

What is Sopharma AD-Sofia Notes Receivable?

Sopharma AD-Sofia WAR:SPH 66 Notes Receivable is zł0 Mil as of Mar. 2026. GuruFocus rates WAR:SPH with a GF Score™ of 66/100 and a GF Value™ of zł13.51 (Possible Value Trap). The stock has 3 warning signs investors should review.

Sopharma AD-Sofia's Notes Receivable for the quarter that ended in Mar. 2026 was zł0 Mil.

Sopharma AD-Sofia Notes Receivable Related Terms

Sopharma AD-Sofia Notes Receivable Historical Data

* Premium members only.

The historical data trend for Sopharma AD-Sofia's Notes Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sopharma AD-Sofia Notes Receivable Chart

Sopharma AD-Sofia Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Notes Receivable
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Sopharma AD-Sofia Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Notes Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
WAR:SPH
66GF Score
Sopharma AD-Sofia WAR:SPH
Notes Receivable is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Sopharma AD-Sofia Notes Receivable Calculation

Notes Receivable is an unconditional promise to receive a definite sum of money at a future date(s) within one year of the balance sheet date or the normal operating cycle, whichever is longer.

Frequently Asked Questions Learn more about Notes Receivable →
What does a Notes Receivable of zł0 Mil mean?
Sopharma AD-Sofia (WAR:SPH) has a Notes Receivable of zł0 Mil as of Mar. 2026. Notes Receivable is an unconditional promise to receive a definite sum of money within one year. View historical data on Sopharma AD-Sofia and its competitors.
Is Sopharma AD-Sofia's Notes Receivable too high?
Sopharma AD-Sofia's current Notes Receivable is zł0 Mil. Overall, Sopharma AD-Sofia has a GF Score™ of 66/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Sopharma AD-Sofia's Notes Receivable compare to MCK and CAH?
Sopharma AD-Sofia's Notes Receivable of zł0 Mil can be compared against companies in the Medical Distribution industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Notes Receivable for a Medical Distribution company?
A good Notes Receivable depends on the Medical Distribution industry context. However, Notes Receivable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Notes Receivable mean?
A high Notes Receivable can signal that a stock is expensive relative to its fundamentals. Notes Receivable is an unconditional promise to receive a definite sum of money within one year. View historical data on Sopharma AD-Sofia and its competitors. Sopharma AD-Sofia's current Notes Receivable is zł0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sopharma AD-Sofia stock overvalued right now?
Based on GuruFocus' analysis, Sopharma AD-Sofia (WAR:SPH) is currently considered Possible Value Trap. The stock's GF Value™ is zł13.51, compared to a current price of zł7.70 — trading 43% below its estimated fair value. The current Notes Receivable is zł0 Mil. Sopharma AD-Sofia's overall GF Score™ is 66/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Notes Receivable calculated?
Notes Receivable is calculated from a company's financial statements. For Sopharma AD-Sofia (WAR:SPH), the current Notes Receivable is zł0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Sopharma AD-Sofia (WAR:SPH) Overvalued in 2026?

Based on GuruFocus' analysis, Sopharma AD-Sofia stock appears to be undervalued. The current stock price of zł7.70 is trading 43% below its estimated GF Value™ of zł13.51. GuruFocus considers Sopharma AD-Sofia to be Possible Value Trap.

Key valuation signals for WAR:SPH:

  • Notes Receivable: zł0 Mil
  • GF Value™: zł13.51 vs. price of zł7.70 (43% below fair value)
  • GF Score™: 66/100 with 3 warning signs

No single metric tells the full story. See the WAR:SPH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Sopharma AD-Sofia Business Description

Other Exchanges 3JR:GermanySFA:Bulgaria
Address 5 Lachezar Stanchev Street, Sopharma Business Towers, Building A, Floor 12, Sofia, BGR, 1756
Sopharma AD-Sofia is a company engaged in the production of pharmaceutical products. Its principal activities include the production and trade of medicinal substances and finished drug forms; and research and development as well as engineering and implementation activities in the field of medicinal products. It is also focused on the distribution of pharmaceuticals like medical supplies, sanitary materials, vitamins, food supplements, and cosmetics. The company's segments are the Production of pharmaceutical products; Distribution of pharmaceutical products. It generates the majority of its revenue from the Distribution of pharmaceutical products.
66GF Score

Get the complete analysis for WAR:SPH

Notes Receivable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

zł7.70
Price
zł13.51
GF Value